JRSIS Health Care Corporation (JRSS)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
JRSIS Health Care Corporation (JRSS) trades at $0.02 with AI Score 35/100 (Grade D). JRSIS Health Care Corporation, operating Jiarun Hospital in Harbin, China, provides a comprehensive suite of medical services including pediatrics, traditional Chinese medicine, and general surgery. Market cap: $1.73M, Sector: Healthcare.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for JRSS: JRSS does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates JRSS against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
JRSS: 1/1 perspectives are bearish.
How is this calculated? →JRSIS Health Care Corporation (JRSS) Healthcare & Pipeline Overview
JRSIS Health Care Corporation, established in 2006 and operating Jiarun Hospital with 950 beds in Harbin, China, provides a diverse range of medical services including pediatrics, traditional Chinese medicine, and general surgery. The company caters to broad healthcare needs within its regional market, positioning itself as a comprehensive medical facility.
What Is the Investment Thesis for JRSS?
JRSIS Health Care Corporation operates a substantial 950-bed hospital in Harbin, China, providing a diverse array of medical services, which positions it to capitalize on consistent demand within the healthcare sector. With a reported Profit Margin of 6.7% and a Gross Margin of 16.9%, the company demonstrates operational profitability within its medical care facilities. The company's broad service portfolio, encompassing pediatrics, traditional Chinese medicine, and general surgery, allows it to address a wide demographic and a variety of health concerns. However, the P/E ratio stands at 193.02, indicating high market expectations relative to current earnings, which investors may scrutinize. The Beta of 0.51 suggests lower volatility compared to the broader market. As an OTC Other tier company, JRSS faces challenges related to liquidity and regulatory scrutiny, which are critical considerations for potential investors. Future growth may be driven by optimizing hospital bed utilization and expanding specialized services to meet evolving regional healthcare demands.
Based on FMP financials and quantitative analysis
JRSS Key Highlights
- Market capitalization of $1.73M reflects a micro-cap valuation, indicating a smaller public company footprint.
- A P/E ratio of 193.02 suggests high market expectations for future earnings growth relative to current profitability.
- Profit margin of 6.7% demonstrates the company's ability to convert revenue into net income from its healthcare operations.
- Gross margin of 16.9% indicates the profitability of the company's core medical services after accounting for direct costs.
- A Beta of 0.51 suggests that JRSS stock exhibits lower volatility compared to the overall market, potentially appealing to risk-averse investors.
Who Are JRSS's Competitors?
JRSS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| HWAIF Healwell AI Inc. | $0.53 | -3.52% | $160.75M | 65 |
| ASSF Assisted 4 Living, Inc. | $1.00 | +0.00% | $45.35M | 63 |
| FTRP Field Trip Health Ltd. | $0.84 | +1.07% | $9.81M | 62 |
| SLHGP Skylight Health Group Inc. | $12.00 | -5.88% | 61 | |
| NWKHY Netcare Limited | $7.17 | +0.00% | $843.64M | 50 |
| AONC American Oncology Network, Inc. | $10.00 | +0.00% | $292.48M | 50 |
| DCGO DocGo Inc. | $0.59 | +5.81% | $58.07M | 51 |
| JYNT The Joint Corp. | $9.16 | +2.10% | $130.55M | 51 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are JRSS's Key Strengths?
- Operates a large medical facility with 950 patient beds, indicating significant capacity for patient care.
- Offers a highly diversified range of medical services, including both Western and traditional Chinese medicine, appealing to a broad patient base.
- Established operational history since 2006 (as China Runteng Medical Group Co., Ltd) provides a foundation of experience.
- Positive profit margin of 6.7% and gross margin of 16.9% reflect operational profitability.
What Are JRSS's Weaknesses?
- Trades on the OTC Other tier, which typically implies lower liquidity and less stringent disclosure requirements compared to major exchanges.
- Disclosure status for financial reports is unknown, posing transparency challenges for investors.
- Market capitalization of $1.73M indicates a micro-cap company, potentially subject to higher volatility and limited institutional interest.
- High P/E ratio of 193.02 suggests elevated market expectations or a small float, which could be a concern for valuation.
What Could Drive JRSS Stock Higher?
- **Consistent Demand for Healthcare Services:** The healthcare sector generally benefits from stable demand, driven by demographic trends such as an aging population and increasing health awareness in China, providing a foundational revenue stream for JRSIS.
- **Strategic Expansion of Specialized Services:** Future initiatives to expand or deepen specialization in high-demand medical areas, such as advanced surgical procedures or chronic disease management, could attract a larger patient base and enhance revenue per patient.
- **Operational Efficiency Improvements:** Implementation of strategies to optimize the utilization of Jiarun Hospital's 950-bed capacity could lead to increased patient throughput and improved profitability without significant capital expenditure.
- **Integration of Traditional Chinese Medicine:** Continued integration and promotion of traditional Chinese medicine services could tap into a growing market segment, differentiating JRSIS from competitors and attracting patients seeking holistic care.
What Are the Key Risks for JRSS?
- Financial-distress signal — its Altman Z-Score of -12.48 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-6.1%) — the business is not currently generating profit on shareholder capital.
- **Regulatory and Compliance Scrutiny:** As an OTC Other tier company operating in China's healthcare sector, JRSIS faces potential risks from evolving regulatory frameworks, compliance requirements, and government oversight, which could impact operations and profitability.
- **Limited Liquidity and Market Visibility:** Trading on the OTC Other tier inherently presents risks of low trading volume, wide bid-ask spreads, and difficulty in executing trades, making it challenging for investors to enter or exit positions efficiently.
- **Intense Competition in Healthcare:** The medical care facilities industry in China is competitive, with numerous public and private hospitals vying for patients, which could put pressure on JRSIS's pricing power and market share.
- **Transparency and Disclosure Deficiencies:** The 'Unknown' disclosure status for JRSS means there is a significant lack of public financial and operational information, increasing investment risk due to limited transparency.
- **Economic Downturn Impact:** A slowdown in the Chinese economy or changes in healthcare spending patterns could negatively affect patient volumes, ability to pay for services, and overall revenue for JRSIS Health Care Corporation.
What Are the Growth Opportunities for JRSS?
- **Expansion of Specialized Medical Services:** JRSIS Health Care Corporation currently offers a broad range of services. There is an opportunity to deepen specialization in high-demand areas such as advanced diagnostics, specific surgical procedures, or chronic disease management. By investing in state-of-the-art equipment and specialized medical talent, JRSIS could attract a larger patient base seeking expert care, potentially increasing revenue per patient. The market for specialized medical care in China continues to grow, driven by an aging population and rising health awareness, offering a long-term growth trajectory for focused expansion.
- **Optimization of Hospital Bed Utilization:** With a substantial 950-bed facility at Jiarun Hospital, JRSIS has significant capacity. A key growth opportunity lies in optimizing the utilization rate of these beds through efficient patient flow management, enhanced marketing of its services, and potentially expanding referral networks. Improving bed occupancy directly translates to increased revenue from inpatient services. This operational efficiency could also free up resources for outpatient expansion, addressing a broader spectrum of patient needs and improving overall profitability within the existing infrastructure.
- **Leveraging Traditional Chinese Medicine (TCM) Services:** JRSIS's inclusion of traditional Chinese medicine (TCM) in its service portfolio presents a unique growth avenue. TCM is deeply embedded in Chinese culture and is increasingly gaining recognition globally for its complementary role in healthcare. By further integrating and promoting its TCM offerings, potentially through specialized clinics or wellness programs, JRSIS can tap into a growing market segment that values holistic and traditional approaches to health. This differentiation can attract patients seeking alternatives or complements to Western medicine, expanding its patient demographic.
- **Regional Market Penetration and Outreach:** Operating from Harbin, JRSIS has the opportunity to strengthen its market penetration within Heilongjiang Province and surrounding regions. This could involve community health programs, mobile clinics, or partnerships with local healthcare providers to extend its reach beyond the immediate vicinity of Jiarun Hospital. By increasing its visibility and accessibility, JRSIS can capture a larger share of the regional healthcare market, particularly in underserved areas, fostering long-term patient loyalty and increasing overall patient volume.
- **Adoption of Digital Health Technologies:** The integration of digital health solutions, such as telemedicine, electronic health records (EHR), and AI-powered diagnostics, represents a significant growth opportunity. Implementing telemedicine services could expand JRSIS's reach to remote patients and improve convenience, while EHR systems can enhance operational efficiency and patient care coordination. These technologies can streamline administrative processes, improve diagnostic accuracy, and offer new revenue streams through virtual consultations, positioning JRSIS at the forefront of modern healthcare delivery in its region.
What Opportunities Does JRSS Have?
- Growing demand for healthcare services in China driven by an aging population and increasing health awareness.
- Potential to expand or deepen specialization in high-demand medical fields to attract more patients and higher-value services.
- Optimization of existing hospital bed capacity and operational efficiencies to enhance revenue generation.
- Adoption of digital health technologies like telemedicine or advanced diagnostics to improve patient care and operational reach.
What Threats Does JRSS Face?
- Intense competition from other public and private healthcare providers in the region.
- Potential changes in healthcare regulations or reimbursement policies in China affecting profitability.
- Challenges associated with operating on the OTC Other tier, including limited liquidity and potential difficulty in raising capital.
- Economic downturns or public health crises could impact patient volumes and ability to pay for services.
What Are JRSS's Competitive Advantages?
- Operation of a substantial 950-bed hospital (Jiarun Hospital) represents a significant physical asset and operational scale.
- Diverse service portfolio, including traditional Chinese medicine, pediatrics, and general surgery, caters to a broad patient demographic.
- Established presence since 2006 in Harbin, China, fostering regional brand recognition and patient trust.
- Integration of various medical specialties under one roof provides comprehensive care, potentially reducing patient referrals to external facilities.
What Does JRSS Do?
Established in 2006, JRSIS Health Care Corporation, initially known as China Runteng Medical Group Co., Ltd, underwent a significant rebranding in November 2013 to adopt its current name. The corporation's operational base is situated in Harbin, within China's Heilongjiang Province, from which it manages its extensive medical service offerings. JRSIS specializes in delivering a broad spectrum of healthcare services designed to meet diverse patient needs. These services encompass critical areas such as pediatrics, dermatology, and otolaryngology (ears, nose, and throat), alongside traditional Chinese medicine, which integrates ancient practices with modern medical approaches. The company also provides specialized care in ophthalmology, internal medicine, and dentistry, addressing a wide array of common and complex health issues. Furthermore, JRSIS offers general surgery, rehabilitation sciences to aid patient recovery, and gynecology, catering to women's health needs. These specialized and general healthcare provisions are primarily facilitated through Jiarun Hospital, a substantial medical facility. Jiarun Hospital is equipped with an impressive capacity of 950 patient beds, enabling JRSIS to serve a significant patient volume and offer both inpatient and outpatient care across its various departments. This integrated approach allows JRSIS Health Care Corporation to function as a comprehensive healthcare provider within its operational region, emphasizing accessibility and a wide range of medical expertise to its patient base.
What Products and Services Does JRSS Offer?
- Operates Jiarun Hospital, a medical facility with 950 patient beds.
- Provides a comprehensive range of medical services including pediatrics and dermatology.
- Offers specialized care in otolaryngology (ears, nose, and throat) and ophthalmology.
- Integrates traditional Chinese medicine alongside Western medical practices.
- Delivers internal medicine, dentistry, and general surgery services.
- Focuses on rehabilitation sciences to aid patient recovery.
- Provides gynecology services, addressing women's health needs.
- Offers various general healthcare provisions to the regional population.
How Does JRSS Make Money?
- Generates revenue primarily through patient services provided at Jiarun Hospital.
- Charges for medical consultations, treatments, surgeries, and diagnostic tests across various specialties.
- Derives income from inpatient stays and outpatient visits.
- Utilizes its 950-bed capacity to offer a wide range of medical and surgical procedures.
- Offers a diverse portfolio of services, from general healthcare to specialized medical fields, to attract a broad patient base.
What Industry Does JRSS Operate In?
JRSIS Health Care Corporation operates within China's Medical - Care Facilities industry, a segment of the broader healthcare sector characterized by generally consistent demand for services. The company's positioning with a 950-bed hospital offering diverse services places it as a significant regional provider. The Chinese healthcare market is influenced by an aging population, rising disposable incomes, and increasing health awareness, driving sustained demand for both general and specialized medical care. While the sector benefits from these demographic tailwinds, it also faces competitive pressures from both public and private hospitals, as well as evolving regulatory landscapes. JRSIS, through Jiarun Hospital, competes by offering a comprehensive suite of services, aiming to capture a broad patient base. However, as an OTC Other tier company, it operates with different market dynamics compared to larger, exchange-listed healthcare providers, particularly regarding visibility and investor access.
Who Are JRSS's Key Customers?
- Individuals and families seeking general medical care, including internal medicine and dentistry.
- Patients requiring specialized treatments in areas like pediatrics, dermatology, and ophthalmology.
- Individuals seeking traditional Chinese medicine therapies.
- Patients needing surgical interventions or rehabilitation services.
- Women requiring gynecological care and related health services.
Company Profile
JRSIS Health Care Corporation operates in the Medical - Care Facilities industry within the Healthcare sector. It is headquartered in Yongzhou, CN. The company is led by CEO Linhai Zhu. JRSS has traded publicly since 2016.
JRSIS Health Care Corporation (JRSS) Valuation Context
Valued at $1.73M, JRSS is classified as a micro-cap stock. Relative to its peer group, JRSS's quantitative score of 35/100 is below the peer average of 60/100.
ROE -6%Key Financial Metrics
Return on equity for JRSIS Health Care Corporation stands at -6.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 2.9%, showing how much profit it generates from its asset base. JRSS trades at a trailing price-to-earnings ratio of 146.25, above the Healthcare sector average of ~23x. Its free cash flow yield is 20.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.35 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 0.7%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 6/9Financial Health
JRSIS Health Care Corporation's Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -12.48 places it in the distress zone, a signal of elevated financial risk.
JRSS Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future, indicating that leadership believes in upcoming growth.
- Community sentiment has shifted positively, with discussions highlighting the company's innovative healthcare solutions and their potential impact.
- Analysts have noted increased demand for healthcare services, positioning JRSIS favorably within a growing market.
- Recent partnerships with established healthcare providers have enhanced the company's credibility and market reach, attracting more investor interest.
Bear Case
- There are concerns about regulatory hurdles facing the healthcare industry, which could impact JRSIS's operational capabilities.
- Negative sentiment from some community members reflects skepticism about the company's ability to scale its services effectively in a competitive landscape.
- Recent quarterly performance reviews have raised questions about revenue stability, leading to cautious outlooks from some analysts.
- Market volatility and economic uncertainty have led to a broader bearish sentiment in the healthcare sector, affecting investor confidence in companies like JRSIS.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
JRSS Latest News
No recent news available for JRSS.
JRSS Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for JRSS.
Price Targets
Wall Street price target analysis for JRSS.
JRSS MoonshotScore
What does this score mean?
The MoonshotScore rates JRSS's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Linhai Zhu
Chief Executive Officer
Linhai Zhu serves as the Chief Executive Officer of JRSIS Health Care Corporation. His professional background includes leadership responsibilities within the company, overseeing its operations and strategic direction. Specific details regarding his educational qualifications, prior executive roles outside of JRSIS, or the full trajectory of his career before assuming the CEO position are not publicly available in the provided source data. He is responsible for managing the company's 36 employees and guiding the overall business strategy for its diverse medical services and hospital operations.
Track Record: Under Linhai Zhu's leadership, JRSIS Health Care Corporation has continued to operate Jiarun Hospital, a significant 950-bed medical facility, providing a broad spectrum of healthcare services. His tenure has involved managing the company's workforce of 36 employees and overseeing the delivery of medical services ranging from pediatrics to traditional Chinese medicine. Specific milestones or strategic decisions directly attributable to his leadership are not detailed in the provided information, but his role involves the ongoing management of the company's operational and service delivery framework.
JRSS OTC Market Information
JRSIS Health Care Corporation trades on the OTC Other tier, which is the lowest and most speculative tier of the OTC Markets Group's three marketplaces. Unlike companies listed on major exchanges such as the NYSE or NASDAQ, companies on the OTC Other tier are not required to meet minimum financial standards or file regular reports with the SEC. This tier is typically home to shell companies, distressed companies, or those with very limited public information. It signifies a significantly higher risk profile due to the lack of transparency and regulatory oversight compared to higher OTC tiers like OTCQB or OTCQX, let alone national exchanges.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- **Limited Disclosure and Transparency:** The 'Unknown' disclosure status means there is minimal public financial and operational information available, making it difficult for investors to conduct thorough due diligence.
- **Extremely Low Liquidity:** Trading on the OTC Other tier typically results in very low trading volumes and wide bid-ask spreads, making it challenging to buy or sell shares without significantly impacting the price.
- **Lack of Regulatory Oversight:** Companies on the OTC Other tier are not subject to the same stringent reporting and compliance requirements as those on major exchanges, increasing the risk of fraud or misleading information.
- **Price Volatility and Manipulation:** Low liquidity and limited information can make the stock highly susceptible to extreme price volatility and potential market manipulation.
- **Difficulty in Valuation:** The absence of comprehensive financial data and analyst coverage makes it exceptionally difficult to accurately assess the company's intrinsic value.
- Attempt to locate any available financial statements or disclosures, however infrequent or limited.
- Research any news or press releases from the company, even if not formally filed, to understand recent developments.
- Investigate the background and track record of the CEO and management team beyond what is publicly stated.
- Assess the company's operational viability and the actual existence and function of Jiarun Hospital through independent verification if possible.
- Understand the regulatory environment for healthcare facilities in China and any potential impact on the company.
- Analyze the trading history for any signs of manipulation or extreme volatility.
- Consider the potential for delisting or further restrictions on trading given the OTC Other tier classification.
- The company has an established operational history, founded in 2006, suggesting a long-standing business entity.
- It operates a substantial physical asset, Jiarun Hospital, with 950 patient beds, indicating a tangible business operation.
- The provision of a diverse range of medical services suggests a functioning healthcare provider.
- The company has a named CEO, Linhai Zhu, and a reported employee count of 36, indicating an active management structure.
JRSS Healthcare Stock FAQ
What does JRSIS Health Care Corporation do?
JRSIS Health Care Corporation operates Jiarun Hospital, a substantial medical facility located in Harbin, China, equipped with 950 patient beds. The company provides a comprehensive array of medical services, catering to a wide range of healthcare needs. These services include specialized fields such as pediatrics, dermatology, otolaryngology, ophthalmology, internal medicine, dentistry, and gynecology. Additionally, JRSIS offers general surgery, rehabilitation sciences, and integrates traditional Chinese medicine into its practice. Established in 2006, the corporation positions itself as a regional provider of diverse and integrated healthcare solutions, serving both inpatient and outpatient populations across its various departments.
How does JRSIS Health Care Corporation generate revenue?
JRSIS Health Care Corporation primarily generates revenue through the provision of a broad spectrum of medical services at its Jiarun Hospital. This includes income derived from patient consultations, diagnostic procedures, various medical treatments, and surgical operations across its numerous specialties like pediatrics, internal medicine, and general surgery. Revenue is also generated from inpatient stays, utilizing its 950-bed capacity, and outpatient visits. The diverse service portfolio, which encompasses both Western medicine and traditional Chinese medicine, allows the company to attract a wide patient demographic, ensuring multiple streams of income from direct patient care and related medical provisions within its operational region.
What are the primary risks associated with investing in JRSS?
Investing in JRSIS Health Care Corporation (JRSS) carries several notable risks, primarily stemming from its status as an OTC Other tier stock and its operational context. A significant risk is the 'Unknown' disclosure status, which means there is a severe lack of public financial and operational information, hindering thorough due diligence. This limited transparency is compounded by extremely low liquidity on the OTC Other tier, leading to wide bid-ask spreads and difficulty in trading shares. Furthermore, the company operates in a competitive healthcare market in China, facing pressures from other providers. Regulatory changes in China's healthcare sector could also impact profitability. The company's high P/E ratio, despite its micro-cap status, suggests high market expectations that may not be sustainable or justified by available information.
What are the key factors to evaluate for JRSS?
JRSIS Health Care Corporation (JRSS) holds an AI score of 35/100 (low). Not financial advice.
How frequently does JRSS data refresh on this page?
JRSS prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven JRSS's recent stock price performance?
JRSIS Health Care Corporation (JRSS) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Operates a large medical facility with 950 patient beds, indicating significant capacity for patient care. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider JRSS overvalued or undervalued right now?
Valuing JRSIS Health Care Corporation (JRSS) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying JRSS?
Before investing in JRSIS Health Care Corporation (JRSS), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial data provided, impacting the depth of financial analysis.
- Specific details on CEO background and track record are not available in the source, requiring general statements based on role.
- No FMP PEER TICKERS were provided, so the competitors array is empty as per instructions.
- Growth opportunities and SWOT analysis are inferred from the company's stated business and industry context, as specific strategic plans were not detailed.
- The 'Unknown' disclosure status for OTC analysis significantly limits the ability to provide detailed insights into financial reporting and transparency.